Antengene Valuation

Q: How does 6996's PS Ratio compare to its peers?

Insufficient data to answer this question

Q: How does 6996's PS Ratio compare vs other companies in the HK Pharmaceuticals Industry?

Insufficient data to answer this question

Q: What is 6996's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to answer this question

Q: What is the Fair Price of 6996 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to answer this question

Q: What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to answer this question

Is 6996 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Share Price vs Fair Value

What is the Fair Price of 6996 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6996?

Key metric:

The above table shows the Price to Sales ratio for 6996. This is calculated by dividing 6996's market cap by their current revenue.
What is 6996's PS Ratio?
PS Ratio	9.4x
Sales	CN¥56.07m
Market Cap	CN¥527.57m

6996 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6996's PS Ratio compare to its peers?

The above table shows the PS ratio for 6996 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.5x
239 Pak Fah Yeow International	2.9x	n/a	HK$776.0m
1652 Fusen Pharmaceutical	1x	n/a	HK$436.2m
455 Tianda Pharmaceuticals	1.1x	n/a	HK$387.0m
8049 Jilin Province Huinan Changlong Bio-pharmacy	0.9x	n/a	HK$806.8m
6996 Antengene	9.4x	66.1%	HK$591.1m

Price to Sales Ratio vs Industry

How does 6996's PS Ratio compare vs other companies in the HK Pharmaceuticals Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
3320 China Resources Pharmaceutical Group	0.1x	7.6%	US$4.07b
8329 Shenzhen Neptunus Interlong Bio-technique	0.2x	n/a	US$34.47m
1312 Kontafarma China Holdings	0.2x	n/a	US$21.52m

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap

No more companies

Price to Sales Ratio vs Fair Ratio

What is 6996's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6996 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	9.4x
Fair PS Ratio	14.3x

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target

Consensus Narrative from 2 Analysts

HK$1.65

Fair Value

49.7% undervalued

Number of Analysts

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/23 17:42
End of Day Share Price	2025/01/23 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Antengene Corporation Limited is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ziyu He	China International Capital Corporation Limited
Wangbin Zhou	Citigroup Inc
Ruili Bian	Citigroup Inc